Uncategorized

Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin Clinical Trial by Health Canada

Apex Labs Ltd. is pleased to announce approval of SUMMIT-90. SUMMIT-90 is a landmark double-blind, placebo controlled phase 2b study evaluating multiple doses of APEX-90 administered in-clinic with assisted psychotherapy for the treatment of severe depression within diagnosed PTSD.

Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin Clinical Trial by Health Canada Read More »

NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

Lannett Company, Inc. (LCI) (“Lannett” or “the Company”) today announced that it received a written notice from the New York Stock Exchange (“NYSE”) dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company’s common stock from the NYSE.

NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS Read More »

Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer

Immunovia announced it will participate in a webinar titled “Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer” hosted by the National Pancreas Foundation on April 26, 2023, at 7:00 pm ET.

Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer Read More »

Scroll to Top